A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BORTEZOMIB AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Jakubowiak, A. [1 ]
Offidani, M. [2 ]
Pegourie, B. [3 ]
De La Rubia, J. [4 ]
Garderet, L. [5 ]
Laribi, K. [6 ]
Bosi, A. [7 ]
Marasca, R. [8 ]
Laubach, J. [9 ]
Mohrbacher, A. [10 ]
Carella, A. M. [11 ]
Singhal, A. K. [12 ]
Tsao, L. C. [12 ]
Lynch, M. [13 ]
Bleickardt, E. [13 ]
Jou, Y. M. [13 ]
Palumbo, A. [14 ]
机构：
[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[2] Osped Riuniti Ancona, Azienda Osped Univ, Ancona, Italy
[3] Hop Albert Michallon, CHU Grenoble, Grenoble, France
[4] HUP La Fe, Valencia, Spain
[5] Hop St Antoine, F-75571 Paris, France
[6] Ctr Hosp, Le Mans, France
[7] Azienda Osped Univ Careggi, Florence, Italy
[8] Azienda Osped Univ, Policlin Modena, Modena, Italy
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
[10] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[11] IRCCS San Martino IST, Genoa, Italy
[12] AbbVie Biotherapeut Inc ABR, Redwood City, CA USA
[13] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[14] Osped Molinette, Azienda Osped Univ San Giovanni Battista Torino, Turin, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S103
引用
收藏
页码：2 / 2
页数：1
相关论文
共 50 条
  • [31] Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study
    Grammatico, Sara
    Bringhen, Sara
    Vozella, Federico
    Siniscalchi, Agostina
    Boccadoro, Mario
    Petrucci, Maria Teresa
    LEUKEMIA & LYMPHOMA, 2017, 58 (11) : 2738 - 2740
  • [32] A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Hajek, Roman
    Pour, Ludek
    Ozcan, Muhit
    Sanchez, Jesus Martin
    Sanz, Ramon Garcia
    Anagnostopoulos, Achilles
    Oriol, Albert
    Cascavilla, Nicola
    Terjung, Andreas
    Lee, Yihua
    Briso, Eva M.
    Dobkowska, Edyta
    Hauns, Bernhard
    Spicka, Ivan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 435 - 442
  • [33] Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
    Laubach, Jacob P.
    Schjesvold, Fredrik
    Mariz, Mario
    Dimopoulos, Meletios A.
    Lech-Maranda, Ewa
    Spicka, Ivan
    Hungria, Vania T. M.
    Shelekhova, Tatiana
    Abdo, Andre
    Jacobasch, Lutz
    Polprasert, Chantana
    Hajek, Roman
    Illes, Arpad
    Wrobel, Tomasz
    Sureda, Anna
    Beksac, Meral
    Goncalves, Iara Z.
    Blade, Joan
    Rajkumar, S. Vincent
    Chari, Ajai
    Lonial, Sagar
    Spencer, Andrew
    Maison-Blanche, Pierre
    Moreau, Philippe
    San-Miguel, Jesus F.
    Richardson, Paul G.
    LANCET ONCOLOGY, 2021, 22 (01): : 142 - 154
  • [34] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Iida, Shinsuke
    Nagai, Hirokazu
    Kinoshita, Gen
    Miyoshi, Masafumi
    Robbins, Michael
    Pandya, Dimple
    Bleickardt, Eric
    Chou, Takaaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 326 - 334
  • [35] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Shinsuke Iida
    Hirokazu Nagai
    Gen Kinoshita
    Masafumi Miyoshi
    Michael Robbins
    Dimple Pandya
    Eric Bleickardt
    Takaaki Chou
    International Journal of Hematology, 2017, 105 : 326 - 334
  • [36] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
    Richardson, Paul G.
    Oriol, Albert
    Beksac, Meral
    Liberati, Anna Marina
    Galli, Monica
    Schjesvold, Fredrik
    Lindsay, Jindriska
    Weisel, Katja
    White, Darrell
    Facon, Thierry
    Miguel, Jesus Son
    Sunami, Kazutaka
    O'Gorman, Peter
    Sonneveld, Pieter
    Robak, Pawel
    Semochkin, Sergey
    Schey, Steve
    Yu, Xin
    Doerr, Thomas
    Bensmaine, Amine
    Biyukov, Tsvetan
    Peluso, Teresa
    Zaki, Mohamed
    Anderson, Kenneth
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2019, 20 (06): : 781 - 794
  • [37] Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
    Gonsalves, Wilson I.
    Kumar, Shaji
    Perez, Gabriela
    Saathoff, Stephanie
    Wilson, Diana M.
    Young, Anna
    Ailawadhi, Sikander
    BLOOD, 2021, 138
  • [38] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
    Dunn, Tamara J.
    Dinner, Shira
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Hao, Ying
    Berube, Caroline
    Medeiros, Bruno C.
    Liedtke, Michaela
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
  • [39] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
    Shinsuke Iida
    Tohru Izumi
    Takuya Komeno
    Yasuhito Terui
    Takaaki Chou
    Takashi Ikeda
    Deborah Berg
    Shinichi Fukunaga
    Kenkichi Sugiura
    Makoto Sasaki
    International Journal of Clinical Oncology, 2022, 27 : 224 - 233
  • [40] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
    Iida, Shinsuke
    Izumi, Tohru
    Komeno, Takuya
    Terui, Yasuhito
    Chou, Takaaki
    Ikeda, Takashi
    Berg, Deborah
    Fukunaga, Shinichi
    Sugiura, Kenkichi
    Sasaki, Makoto
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 224 - 233
12345